Elbit Medical Technologies - Full-year financial results
Elbit Medical Technologies’ two portfolio investments continue to advance on multiple fronts. InSightec recently completed its compatibility project with Siemens MR scanners and its ExAblate Neuro units, which lends the opportunity to expand its presence in the global MR market. According to Gamida Cell, its cash balance should fund its operations through the top-line readout of its Phase III study of NiCord, which is expected in H120.Elbit Medical Technologies Ltd is an Israel-based company engaged in the healthcare sector. It is a holding Company which was established in order to gather all of Elbit groups' bio medical and medical devices investments under one entity. Elbit Medical Technologies Ltd's medical division includes investment in InSightec Ltd that is engaged in the development, production and marketing of magnetic resonance imaging guided ultrasound equipment as well as investment in Gamida Cell Ltd that is engaged in the development of stem cell therapeutics based on its proprietary technologies for stem cell expansion as well as future regenerative cell-based medicines including heart tissue repair.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.